Cue Biopharma, Inc.

CUE

US22978P1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.9402 ^USD	-0.85%		-2.06%	-64.39%

Jul. 01	Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000E Growth Index	CI
Jul. 01	Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Growth Index	CI

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Dynamic Index

July 30, 2024

Latest news about Cue Biopharma, Inc.

Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000E Growth Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Growth Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2500 Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000 Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000 Growth Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Dynamic Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell Small Cap Completeness Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000E Index	Jun. 30	CI
Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2500 Growth Index	Jun. 30	CI
Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee	Jun. 07	CI
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024	Apr. 08
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Jefferies Starts Cue Biopharma With Buy Rating	Mar. 13	MT
Transcript : Cue Biopharma, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating	Nov. 06	MT
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb	Nov. 03	MT
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	Nov. 03	CI
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?	23-09-26	CI

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-09-01 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cue Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9402 USD

Average target price

9.4 USD

Spread / Average Target

+899.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CUE BIOPHARMA, INC.	-64.39%	45.73M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs